The recent success of GLP-1-based therapies for weight loss and metabolic health has attracted considerable attention to this gut hormone. While pharmaceuticals directly activate GLP-1 receptors, nutrition science is now exploring whether dietary components can enhance endogenous GLP-1 activity.

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the intestine and released after eating. It helps regulate metabolism by increasing insulin release when blood glucose rises, reducing glucagon levels, slowing the emptying of the stomach, and promoting feelings of fullness. Because of these effects, GLP-1 plays an important role in blood sugar control and appetite regulation.

Importantly, nutrients themselves can influence GLP-1 secretion. Among them, food-derived bioactive peptides — short protein fragments released during digestion, fermentation, or processing using enzymatic treatments — have emerged as potential nutritional modulators of GLP-1 signalling.

Recent Research Highlighting GLP-1-Active Peptides

Recent studies continue to provide evidence that food-derived peptides may influence GLP-1 signalling across different protein sources. Three recent examples are particularly worth highlighting:

Wu et al. (2025) showed that peptides produced from sodium caseinate, a milk protein, improved blood sugar control in diabetic mice. The peptide preparation increased GLP-1 and insulin levels and reduced DPP-IV activity, the enzyme that normally breaks down GLP-1. The study also reported measurable oral absorption of the isolated peptides.

Zhang et al. (2024) showed that pea protein hydrolysate can stimulate GLP-1 secretion in human enteroendocrine cells. The researchers found that this effect involved nutrient-sensing receptors in intestinal cells, which helped trigger GLP-1 release.

Bhowmick et al. (2026) studied marine fish protein hydrolysates in rats with diet-induced type 2 diabetes. The fish-derived hydrolysates improved blood sugar control and were linked to two proposed mechanisms: GLP-1 agonistic activity and DPP-4 inhibition.

Most Promising Sources of GLP-1-Related Bioactive Peptides

Recent reviews, such as Ignot-Gutiérrez et al. (2024), highlight that both plant and animal proteins can generate bioactive peptides capable of influencing satiety hormones such as GLP-Promising protein sources identified in the literature include:

• Milk proteins (casein and whey)
• Pea proteins
• Soy proteins
• Wheat and barley proteins
• Quinoa and amaranth proteins
• Egg proteins
• Fish and marine proteins

Great Concept, Direction is clear

Commercial interest in “GLP-1-related foods and beverages” is growing as GLP-1 therapies have increased awareness of this metabolic pathway. For now, however, most products use “GLP-1-friendly” positioning rather than making direct claims that their peptides stimulate GLP-1. Selection of nutrients focus mainly on on lean, easily digestible protein sources that may help maintain adequate protein intake while supporting satiety.

What Still Needs to Be Better Understood

Before foods that act as effective or targeted modifiers of GLP-1 pathways through bioactive peptides can be developed, several key scientific and technological challenges must be addressed.

• Peptides stability Another important question is whether these peptides remain in their active form during and after digestion, despite exposure to digestive enzymes and changing pH conditions in the gastrointestinal tract. It is also important to understand whether they can reach and interact with their target receptors. Another important question is whether peptides should be delivered in their final bioactive form or as precursor sequences that are released during digestion by endogenous gastrointestinal enzymes.
• Effective physiological doses It remains unclear what dosing of bioactive peptides is required to produce a measurable GLP-1 response in humans, and whether such concentrations can realistically be achieved through normal food consumption.
• Processing and formulation challenges Food processing conditions may alter peptide structure and activity. Strategies are therefore needed to maintain peptide stability and bioactivity during food processing, storage, and formulation.
• Scalable production Producing bioactive peptides at industrial scale also remains a challenge. Future solutions will likely rely on targeted enzymatic hydrolysis or fermentation processes, rather than costly chemical synthesis of individual peptides.
• Human clinical evidence Most of the current evidence for GLP-1–modulating peptides comes from in vitro studies or animal models. While these studies provide valuable mechanistic insights, well-designed human clinical trials are needed to confirm physiological effects, establish effective doses, and build the strong body of evidence required to demonstrate real health impacts.

Addressing these challenges will be essential for translating promising laboratory findings into next-generation functional foods designed to support metabolic health through GLP-1 pathway modulation.

Final Perspective

Due to the success of GLP-1 medications and increasing health awareness among consumers, demand for functional foods targeting metabolic health is expected to grow. Bioactive peptides derived from food proteins appear to be promising candidates for future food-based molecules capable of influencing GLP-1 pathways.

Further research and development are needed to create science-based functional foods with demonstrated health benefits, but current findings suggest that we are on the right track!

Complete list of references available upon request.